• 1
    Bostwick DG, Cheng L. Precursors of prostate cancer. Histopathology 2012; 60: 427
  • 2
    Epstein JI, Herawi M. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. J Urol 2006; 175: 82034
  • 3
    Gallo F, Chiono L, Gastaldi E, Venturino E, Giberti C. Prognostic significance of high-grade prostatic intraepithelial neoplasia (HGPIN): risk of prostatic cancer on repeat biopsies. Urology 2008; 72: 62832
  • 4
    Montironi R, Mazzucchelli R, Lopez-Beltran A, Scarpelli M, Cheng L. Prostatic intraepithelial neoplasia: its morphological and molecular diagnosis and clinical significance. BJU Int 2011; 108: 1394401
  • 5
    Antonelli A, Tardanico R, Giovanessi L et al. Predicting prostate cancer at rebiopsies in patients with high-grade prostatic intraepithelial neoplasia: a study on 546 patients. Prostate Cancer Prostatic Dis 2011; 14: 1736
  • 6
    Herawi M, Kahane H, Cavallo C, Epstein JI. Risk of prostate cancer on first re-biopsy within one year following a diagnosis of high grade prostatic intraepithelial neoplasia is related to the number of cores sampled. J Urol 2006; 175: 1214
  • 7
    Schoenfield L, Jones JS, Zippe CD et al. The incidence of high-grade prostatic intraepithelial neoplasia and atypical glands suspicious for carcinoma on first-time saturation needle biopsy and the subsequent risk of cancer. BJU Int 2007; 99: 7704
  • 8
    Clouston D, Bolton D. In situ and intraductal epithelial proliferations of prostate: definitions and treatment implications. Part 1: prostatic intraepithelial neoplasia. BJU Int 2012; 109 (Suppl. 3): 226
  • 9
    Lee MC, Moussa AS, Yu C, Kattan MW, Magi-Galluzzi C, Jones JS. Multifocal high grade prostatic intraepithelial neoplasia is a risk factor for subsequent prostate cancer. J Urol 2010; 184: 195862
  • 10
    Stewart J, Fleshner N, Cole H, Toi A, Sweet J. Prognostic significance of α-methylacyl-CoA racemase among men with high grade prostatic intraepithelial neoplasia in prostate biopsies. J Urol 2008; 179: 17515
  • 11
    Morote J, Fernández S, Alaña L et al. PTOV1 expression predicts prostate cancer in men with isolated high-grade prostatic intraepithelial neoplasia in needle biopsy. Clin Cancer Res 2008; 14: 261722
  • 12
    Trock BJ, Brotzman MJ, Mangold LA et al. Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies. BJU Int 2012; 110: 5662
  • 13
    Clark JP, Cooper CS. ETS gene fusions in prostate cancer. Nat Rev Urol 2009; 6: 42939
  • 14
    Mosquera JM, Mehra R, Regan MM et al. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res 2009; 15: 470611
  • 15
    Mosquera JM, Perner S, Genega EM et al. Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res 2008; 14: 33805
  • 16
    Perner S, Mosquera JM, Demichelis F et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol 2007; 31: 8828
  • 17
    Carver BS, Tran J, Gopalan A et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 2009; 41: 61924
  • 18
    Park K, Tomlins SA, Mudaliar KM et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 2010; 12: 5908
  • 19
    Furusato B, Tan SH, Young D et al. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis 2010; 13: 22837
  • 20
    Falzarano SM, Zhou M, Carver P et al. ERG gene rearrangement status in prostate cancer detected by immunohistochemistry. Virchows Arch 2011; 459: 4417
  • 21
    He H, Magi-Galluzzi C, Li J et al. The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with ‘atypical glands suspicious for cancer’. Am J Surg Pathol 2011; 35: 60814
  • 22
    Tomlins SA, Rhodes DR, Perner S et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 6448
  • 23
    Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 2008; 8: 497511
  • 24
    Wang J, Cai Y, Ren C, Ittmann M. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 2006; 66: 834751
  • 25
    Furusato B, van Leenders GJ, Trapman J et al. Immunohistochemical ETS-related gene detection in a Japanese prostate cancer cohort: diagnostic use in Japanese prostate cancer patients. Pathol Int 2011; 61: 40914
  • 26
    Braun M, Goltz D, Shaikhibrahim Z et al. ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer – a comparative study of two monoclonal antibodies. Prostate Cancer Prostatic Dis 2012; 15: 1659
  • 27
    Miettinen M, Wang ZF, Paetau A et al. ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma. Am J Surg Pathol 2011; 35: 43241
  • 28
    Yaskiv O, Rubin B, He H, Falzarano SM, Magi-Galluzzi C, Zhou M. ERG protein expression in human tumors detected by a rabbit monoclonal antibody. Am J Clin Pathol (in press)
  • 29
    Yaskiv O, Zhang X, Simmerman K et al. The utility of ERG/P63 double immunohistochemical staining in the diagnosis of limited cancer in prostate needle biopsies. Am J Surg Pathol 2011; 35: 10628
  • 30
    van Leenders GJ, Boormans JL, Vissers CJ et al. Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice. Mod Pathol 2011; 24: 112838
  • 31
    Kron K, Liu L, Trudel D et al. Correlation of ERG expression and DNA methylation biomarkers with adverse clinicopathologic features of prostate cancer. Clin Cancer Res 2012; 18: 2896904
  • 32
    Minner S, Enodien M, Sirma H et al. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res 2011; 17: 587888
  • 33
    Hoogland AM, Jenster G, van Weerden WM et al. ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer. Mod Pathol 2012; 25: 4719
  • 34
    García-Cruz E, Piqueras M, Ribal MJ et al. Low testosterone level predicts prostate cancer in re-biopsy in patients with high grade prostatic intraepithelial neoplasia. BJU Int 2012; 110: E199E202
  • 35
    Chun FK, Epstein JI, Ficarra V et al. Optimizing performance and interpretation of prostate biopsy: a critical analysis of the literature. Eur Urol 2010; 58: 85164
  • 36
    Roscigno M, Scattoni V, Freschi M et al. Diagnosis of isolated high-grade prostatic intra-epithelial neoplasia: proposal of a nomogram for the prediction of cancer detection at saturation re-biopsy. BJU Int 2012; 109: 132934
  • 37
    Lefkowitz GK, Sidhu GP, Torre P et al. Is repeat prostate biopsy for high-grade prostatic intraepithelial neoplasia necessary after routine 12-core sampling? Urology 2001; 58: 9991003
  • 38
    Lefkowitz GK, Taneja SS, Brown J et al. Follow up interval prostate biopsy 3 years after diagnosis of high grade prostatic intraepithelial neoplasia is associated with high likelihood of prostate cancer, independent of change in prostate specific antigen levels. J Urol 2002; 168: 14158